Pharmaceuticals
Florida Theranostics Brings Cutting-Edge United Imaging Digital PET/CT to Palm Beach County, Florida
The uMI Panorama™ from United Imaging is the first in Florida. HOUSTON, April 10, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, will feature its uMI Panorama at a state-of-the-art new facility inJupiter, FL. Focused on patient-centered and preci...
2025-04-11 00:27
2435
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa ...
2025-04-10 20:00
2599
Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances
* Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals * Abstract honored with prestigious "Abstracts of Distinction" award by AAN Science Committee, recogni...
2025-04-09 20:00
3731
Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in...
2025-04-09 19:54
2855
GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine
YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). With the ap...
2025-04-09 12:00
2566
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...
2025-04-08 15:38
3598
Duality Bio Appoints Hua Mu as Global Chief Medical Officer
SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company...
2025-04-07 12:52
2553
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy fo...
2025-04-07 08:00
2618
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journalNature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for th...
2025-04-06 10:12
3519
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveTuesday, April 15, 2025, with trading to begin on a split-adjusted basi...
2025-04-05 04:05
6247
Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation
BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co.,
Ltd.
2025-04-04 20:58
4672
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with...
2025-04-02 22:00
3209
Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma CSR Highlights * CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. * Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). * Tolerability & Disease Control Rate: Sho...
2025-04-02 15:56
2757
Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion
Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, Ap...
2025-04-02 12:17
2984
Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug A...
2025-04-01 22:00
3043
Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidatesDZD8586 and DZD6008, have been selected for pr...
2025-04-01 18:18
2736
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
TOKYO, April 1, 2025 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte growth factor ...
2025-04-01 14:30
2367
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee ofUSD85.0 million, under the licensing agr...
2025-04-01 08:48
3770
Harbour BioMed Reports Full Year 2024 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its ...
2025-03-31 18:13
3395
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Key Highlights: * Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). * ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS H...
2025-03-31 02:32
3597
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 310 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 289 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 284 media titles]
2026-03-03 15:49
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
8019
